NAD RFQ3 - Zymfentra - TIB - Tumor Necrosis Factor Inhibitors.xlsx

XLSX spreadsheet 47 KB Posted

Attached to
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Solicitation number
HT9402-24-Q-9205
Issued by

About this file

This document is a Request for Quotation (RFQ) for the Department of Defense (DoD) Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) related to newly approved pharmaceutical agents in the Tumor Necrosis Factor Inhibitors drug class. The quotations are due by April 12, 2024, for drugs to be considered at the DoD Pharmacy and Therapeutics (P&T) Committee meeting in May 2024. The RFQ includes details on the formulary scenarios and pricing requirements for the agents to be placed on the DoD Uniform Formulary. Manufacturers are required to submit quotes and additional discounts for retail pharmacy refunds. The UF BPA and UF ADP agreements may be awarded based on the P&T Committee's Uniform Formulary decisions. Detailed instructions, important dates, and points of contact are provided in the RFQ document.

View the file

Other files

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the May 2024 DoD P&T Meeting
DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
Formulary Notes
Class Note(s): Step may apply.

Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#3DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#5DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#9DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#10DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1UFAS1MUniform Formulary
After Step Therapy1 or moreNO QUOTE
20144TGTNNFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

ADP (non-FAMP Discount)

UF ADP Appendix for the May 2024 DoD P&T Meeting
DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
Formulary Notes
Class Note(s): Step may apply.

Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

ADP (WAC Discount)

UF ADP Appendix for the May 2024 DoD P&T Meeting
DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
Formulary Notes
Class Note(s): Step may apply.

Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:May 1-2, 2024
DOD Uniform Formulary Subclass:TUMOR NECROSIS FACTOR INHIBITORSQuotes due:April 12, 2024
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent may be placed before the step.
Scenario 120144TGXX1T2AS1MTier 2
After Step Therapy1 or more
20144TGTNT3AS1MTier 3
After Step Therapy1 or more
If cell highlights red, please confirm intent not to submit a quote

File details come from the government source that posted it. Updated .